Physician profile
Stacy A Paye
NPI 1104016286
$2,032.41
in general payments reported to CMS, 2019-2025
29 companies · $18.83 in 2025
The $18.83 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $245 · 2021: $113 · 2022: $378 · 2023: $541 · 2024: $392 · 2025: $18.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $370.14 | 2019-2023 | |
| Hologic Sales and Service, LLC | $211.27 | 2022-2024 | Thinprep 2000 Processor, Aptima, Coolseal Generator |
| Astellas Pharma US INC | $168.85 | 2023-2024 | Veozah |
| Organon LLC | $148.73 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $125.21 | 2021-2024 | |
| Pfizer INC. | $109.94 | 2019-2022 | |
| Amgen INC. | $107.74 | 2019 | |
| Shield Therapeutics INC | $97.41 | 2022-2024 | Accrufer |
| Exeltis, USA INC. | $85.00 | 2023-2024 | Slynd |
| Aspira Women'S Health INC | $79.82 | 2019-2022 | |
| Therapeuticsmd, INC. | $62.36 | 2019-2021 | |
| Biogen, INC. | $58.18 | 2024 | Zurzuvae |
| Lupin INC. | $52.63 | 2020 | |
| Coopersurgical, INC. | $46.49 | 2024 | Paragard T 380a |
| Smith+Nephew, INC. | $44.24 | 2022-2023 | Pico 7 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $32.73 | 2023-2024 | Axonics, Bulkamid |
| Ethicon US, LLC | $28.56 | 2020 | |
| Avion Pharmaceuticals | $26.72 | 2019-2020 | |
| Millicent US INC | $22.11 | 2024 | Intrarosa, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $22.06 | 2023 | |
| Sage Therapeutics, LLC | $18.44 | 2022 | |
| Medicem INC. | $16.89 | 2023 | |
| Amag Pharmaceuticals, INC. | $15.90 | 2019 | |
| Ascend Therapeutics US, LLC | $15.73 | 2021 | |
| Mission Pharmacal Company | $15.64 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.92 | 2020 | |
| Merck Sharp & Dohme LLC | $12.71 | 2021 | |
| Meditrina | $12.10 | 2023 | |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Paye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.